American Journal of Epidemiology Vol. 153, No. 7 : 628-631
Copyright © 2001 by The Johns Hopkins University School of Hygiene and Public Health
ORIGINAL CONTRIBUTION |
Vaccine Efficacy Trials for Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome Are Feasible in the United States: A Commentary on the HIVNET Vaccine Preparedness Study
1 School of Public Health, University of Alabama at Birmingham, Birmingham, AL.
2 University of Alabama School of Medicine, Birmingham, AL.
Abbreviations: AIDS, acquired immunodeficiency syndrome; CTL, cytotoxic T lymphocytes; HIV, human immunodeficiency virus; HIVNET, HIV Network for Prevention Trials; NIAID; National Institute of Allergy and Infectious Diseases; NIH, National Institutes of Health
 |
INTRODUCTION |
|---|
The Human Immunodeficiency Virus (HIV) Network for Prevention Trials (HIVNET) was established in 1994 to mount HIV/acquired immunodeficiency syndrome (AIDS) vaccine trials (at best) and to prepare for such trials in the future (at least) at both US and international sites (1
, 2). HIVNET has now spawned two new and larger activities sponsored by the National Institutes of Health (NIH): the HIV Vaccine Trials Network and the HIV Prevention Trials Network. The sponsor of HIVNET, the National Institute of Allergy and Infectious Diseases (NIAID), chose not to initiate an efficacy trial during the 5-year life of HIVNET, but the intended site preparedness studies were completed.
The research study presented in this issue of the Journal by Seage et al. (3) is a national effort by investigators representing a veritable "who's who" of HIV epidemiologists in the United States and was sponsored by HIVNET. In nine US cities,
|
NOTES |
|---|
|
REFERENCES |
|---|
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  HIV Vaccine Trials: Here and Now? Journal Watch Infectious Diseases, June 8, 2001; 2001(608): 9 - 9. [Full Text]
|
|